Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Diamyd Medical, a Swedish pharmaceutical company engaged in the development of pharmaceuticals for the treatment of diabetes and pain, has named Peter Zerhouni as the CEO and president with immediate effect.
Subscribe to our email newsletter
Most recently, Zerhouni was serving as the acting president and CEO of the Diamyd Medical since April 201, though he has been involved in all aspects of the company since 2006.
In his tenure in the company, he has played a vital role in driving forward company’s business and clinical trials.
The company’s pain business area consists of development projects that use the company’s proprietary NTDDS (Nerve Targeting Drug Delivery System) platform to administer drugs directly to the nervous system to treat chronic pain.